EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Common pitfalls in oncology drug applications aiming for conditional marketing authorization

Sinan B Sarac iD, Peter Kiely, Simona Stankeviciute, Jorge Camarero, Amy McKee

British Journal of Clinical Pharmacology · 2025

DOI: 10.1111/bcp.16383 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Sinan B Sarac und 4 weiteren Autor:innen. Beteiligte Einrichtung: Parexel International, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Approval, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early approval mechanisms, such as conditional approval in the EU, have been used extensively to provide timely access to therapeutic innovations to cancer patients with unmet medical needs. While based on promising early evidence, such approvals are challenging from many perspectives due to the lack of comprehensive data. The limitation typically relates to data that demonstrates clinical benefit via early endpoints and is only acceptable when the early evidence is particularly convincing to assume that the benefits of early access are greater than the potential harms. This paper describes the requirements for conditional approval and presents common pitfalls in oncology, such as misunderstandings about the strength of evidence from exploratory trials and secondary analyses, lack of planning and opportunities to improve communication. Thereafter, we present a framework (‘EDGE’) on how to improve the submission and evaluation of drug applications for conditional approval in the EU.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDrug ApprovalNeoplasmsHumansClinical Trials as TopicEuropean Union

Stichwörter der Autor:innen

drug developmentprecision medicinerare disease

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Parexel International, Durham, North Carolina, USA.
  • MSD, Madrid, Spain.

ORCID-Profile: Sinan B Sarac

Zitieren

APA

Sarac, S. B., Kiely, P., Stankeviciute, S., Camarero, J., & McKee, A. (2025). Common pitfalls in oncology drug applications aiming for conditional marketing authorization. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16383

Vancouver

Sarac SB, Kiely P, Stankeviciute S, Camarero J, McKee A. Common pitfalls in oncology drug applications aiming for conditional marketing authorization. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16383

BibTeX
@article{Sarac2025,
  author = {Sarac, Sinan B and Kiely, Peter and Stankeviciute, Simona and Camarero, Jorge and McKee, Amy},
  title = {Common pitfalls in oncology drug applications aiming for conditional marketing authorization},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/bcp.16383}
}
Kostenlos starten →